Results from 68-week study of 407 adults with obesity and moderate knee osteoarthritis showed semaglutide 2.4 mg significantly reduced body weight, knee osteoarthritis-related pain, and improved physical function 1 Obesity is a major risk factor of knee osteoarthritis development and disease progression 2-4 Semaglutide is not approved in the U.S.
for the treatment of knee osteoarthritis PLAINSBORO, N.J. , Oct.
30, 2024 /PRNewswire/ -- Today, The New England Journal of Medicine published results from Novo Nordisk's STEP 9 phase 3 clinical trial that studied semaglutide 2.4 mg compared to placebo as an adjunct to lifestyle modifications in reducing body weight and knee osteoarthritis-related pain in adults with obesity, and a clinical and radiologic diagnosis of moderate knee osteoarthritis, and pain that is at least moderately severe. 1 According to the published trial, semaglutide met the study's primary endpoints and was superior to placebo in significantly reducing body weight and knee osteoarthritis-related pain, as measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score.
In addition, the trial met a key confirmatory secondary endpoint of improving patients' physical function. 1 In patients with a mean baseline body weight of 239.5 pounds, semaglutide led to a –13.
7% mean change from baseline in body weight at week 68 versus –3.2% with placebo ([95% confidence interval (CI) –12.3, –8.
6]; P<0.001). Semaglutide also led to a .
